Analysis of the Effect of Empagliflozin in Treating Patients with Coronary Heart Disease Combined with Type 2 Diabetes Mellitus
Objective To investigate the effect of empagliflozin in the treatment of patients with coronary atheroscle-rotic heart disease(hereinafter referred to as"coronary heart disease")complicated with type 2 diabetes.Methods 109 patients with coronary heart disease combined with type 2 diabetes mellitus who were hospitalized in the Depart-ment of Cardiovascular Internal Medicine of the Affiliated Hospital of Chengde Medical College from February 2022 to April 2023 and met the inclusion criteria were selected as the study objects,and were divided into the observation group(59 cases)and the control group(50 cases)using the random number grouping method.Both groups were given conventional coronary heart disease secondary prevention medication.The observation group was given empagliflozin and the control group was given metformin hydrochloride tablets.Blood glucose indexes,lipid indexes,inflammatory factors,coagulation function indexes,blood uric acid,cardiac function indexes and cardiovascular adverse events were compared between the two groups before and after 24 weeks of treatment.Results After treatment,the levels of blood glucose,blood lipids,blood uric acid,and inflammatory factors in the observation group were lower than those of the control group,and the coagulation function and cardiac function of the observation group improved to a superior de-gree after treatment,and the differences were statistically significant(all P<0.05).The incidence rate of cardiovascular adverse events in the observation group was 6.78%lower than 20.00%in the control group,and the difference was sta-tistically significant(χ2=4.226,P=0.040).Conclusion Empagliflozin can regulate blood glucose,lipids,inflammatory response,coagulation process and cardiac function in patients with coronary heart disease accompanied by type 2 dia-betes mellitus,thus reducing the harm caused by heart disease.
NETL
NSTL
万方数据
维普
